KY still pays price for one of nation's highest rates of opioid use disorder, says new report
Kentuckians living with addiction can call Kentucky's help line at 833-859-4357. Narcan, which can help reverse overdoses, is available at pharmacies for sale and through some health departments and outreach programs for free.
Even though overdose deaths have declined over the last three years, Kentucky still has one of the highest rates of opioid use disorder (OUD) in the United States, according to a national report released Tuesday.
'The cost of addiction: Opioid use disorder in the United States' shows Kentucky is one of four states where the rate of opioid use disorder is higher than 2.5% of the population aged 12 or older. The others are New Hampshire, Nevada and Massachusetts.
Margaret Scott, an author of the study from Avalere Health, said the estimate is based on the National Survey on Drug Use. The report doesn't look at factors that might lead to higher or lower rates of cases.
'We did rely on the national figures from the national survey, but this is self reported cases of opioid use disorder, so it is possible that individuals in those states are more likely to self report,' she said.
In 2024, 1,410 Kentuckians died from an overdose, according to the 2024 Drug Overdose Fatality Report. In 2023, there were 1,984 overdose deaths, which was a decrease from the 2,135 lost in 2022.
'It is encouraging to see the number of overdose deaths decreasing,' Scott said. 'We're still seeing 80,000 overdose deaths in the country. It's hard to say what is contributing to that decline (in Kentucky), but we do know that OUD is still a significant problem.'
Ben Mudd, the executive director of the Kentucky Pharmacists Association, said Kentucky does a lot right when it comes to diagnosing and treating addiction.
'There's been a huge focus on harm reduction and naloxone distribution and I think that is why we've seen the decrease in overdose deaths,' Mudd told the Lantern.
But that intervention, which can reverse an overdose, 'doesn't necessarily stop new cases.'
'Those cases still exist,' Mudd said. 'There's so much naloxone out there, people are educated, perhaps people aren't using alone, things like that. All of those programs that have been put in place have led to fewer overdoses, but not necessarily a reduced number of people with opioid use disorder.'
Tuesday's report is mostly interested in the costs surrounding OUD and the economic impact of addiction.
'Some of the costs that we estimated included things like lost income taxes based on the lost productivity for businesses as well as employees' lost wages. We looked at property, client crime from OUD, as well as different types of costs to the state and local governments,' Scott said. 'Those costs included things like Medicaid direct costs for substance use treatment, as well as those lost income taxes and corporate taxes, and then, of course, the criminal justice costs, which would include police presence, courts, jails, all of those things.'
In Kentucky, OUD costs big bucks, according to the report:
Kentucky has one of the highest rates of opioid use disorder in the nation.
Opioid use disorder costs Kentucky about $95 billion, with an average cost per case of $709,441.
State and local governments bear more than $2 billion in costs, primarily driven by criminal justice expenses and lost tax revenue.
The state/local per capita OUD cost is among the highest nationally, between $400-$500 per resident annually.
OUD-related costs in Kentucky are more than 6% of the state's gross domestic product.
'Our study shows that barriers to care include physician stigmatizing and expressing reluctance to treat OUD patients, inadequate provider education and training, geographic distances to treatment locations, and social stigma,' Scott said.
Medicine treatment pays off in the long run, the report says, as it 'has been shown to reduce cravings, increase abstinence from opioids and reduce morbidity and mortality, thereby making it a key component for addressing the economic and public health consequences of OUD.'
Treatments can include medications and therapy. Methadone, buprenorphine and naltrexone are treatments approved by the Food and Drug Administration for OUD management.
'As states and local governments explore new strategies to reduce healthcare costs, encouraging public health, governments and payers to prioritize OUD treatments can lead to greater savings,' Michael Ciarametaro, managing director at Avalere Health, said in a statement.
This is especially true for the formerly incarcerated, who live 'opioid naive' behind bars and may, upon release, take the same dose they did before being incarcerated and not have the resistance to handle it, Mudd explained.
'If you're incarcerated, you hopefully don't have access to opioids. But when you leave that facility, many folks go back to the same routine that they were in before, the same environment they were in before,' he said.
Kentucky has taken aggressive steps to treat and prevent addiction. The latest Drug Overdose Fatality Report showed that for 2024:
$29.8 million was distributed in grant and pass-through funding from the state Office of Drug Control Policy.
170,000 doses of Narcan were distributed.
84 syringe exchange program sites served 27,799 unique participants.
142,312 Kentuckians received addiction services through Medicaid.
17,399 Kentuckians received treatment paid by the Kentucky Opioid Response Effort.
17,984 Kentuckians received recovery services like housing assistance, employment services, transportation and basic needs services in their community paid by the Kentucky Opioid Response Effort.
3,329 incoming calls were made to the KY HELP Call Center with 14,087 outgoing follow up calls.
21 counties are certified as Recovery Ready Communities representing 1,495,518 Kentuckians.
There's still some stigma when it comes to seeking treatment, Mudd said.
'There are folks, even within my profession, that think that this is just a pill mill,' Mudd said. A 'constant turnover' of patients is a 'real thing' and 'a concern of health care providers across the state.'
'It's the nature of addiction and folks with OUD,' he said. 'It's hard to differentiate at the pharmacy counter: 'Is this patient truly in recovery, or is this patient seeking this product so that they can sell it or trade it or whatever for illicit drugs?' And that's tough for pharmacists to make that determination.'
Some won't dispense the treatments, he said, while others say, ''Hey, I want to make sure, just like Naloxone (Narcan), that we see this as a vehicle to help people. Some will use it, some will misuse it, some will divert it.''
Meanwhile, he said, the pharmacist association is focused on making sure pharmacies are 'good access points' for treatments because, especially in rural areas, people may be able to access a pharmacy much easier than a doctor's office.
'If your prescriber, physician, nurse practitioner is 45 minutes an hour away, what we're trying to do is break down those barriers,' Mudd said. 'These products are not available at every drugstore in Kentucky. They're not stocked at Walgreens. They're not stocked at your local independent pharmacy. But we know those are good access points.'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


American Military News
18 hours ago
- American Military News
Video/Pic: Trump demands drug companies lower prices
President Donald Trump sent 17 pharmaceutical companies letters on Thursday and demanded that the companies lower prices for Americans. The president warned that the 'unacceptable burden' of prescription drug prices will 'end' with his administration. During a press briefing on Thursday, White House Press Secretary Karoline Leavitt said, 'The president signed an executive order earlier this year to solve the problem of exorbitant pharmaceutical pricing.' 'According to recent data, the prices that Americans have been paying for brand-name drugs are more than three times the price other similarly developed nations pay,' Leavitt added. 'The president is determined to solve this problem and took further action today. He has signed 17 letters to pharmaceutical companies' CEOs.' .@PressSec reads one of the letters sent by @POTUS today to the CEOs of pharmaceutical companies: "Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices…" — Rapid Response 47 (@RapidResponse47) July 31, 2025 Leavitt also shared the letter Trump wrote to the CEO of Eli Lilly and Company. In the letter, Trump warned Eli Lilly and 16 other pharmaceutical companies that the 'unacceptable burden' of brand-name drugs costing 'up to three times higher on average' for Americans than for citizens of other countries 'ends with my administration.' Trump told the pharmaceutical companies, 'Most proposals the Trump administration has received to resolve this critical issue promised more of the same shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry.' The president added, 'Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices and an end to the free ride of American innovation by European and other developed nations.' READ MORE: Video: Trump order against 'Big Pharma' aims to reduce drug prices While Trump explained that a collaborative effort to reach 'global pricing parity' would be most effective for pharmaceutical companies, the U.S. government, and U.S. patients, he warned that his administration will 'deploy every tool in our arsenal to protect American families' if pharmaceutical companies refuse to take action. In addition to the letter sent to Eli Lilly and Company, Trump sent letters to AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genentech, Gilead Sciences, GSK, Johnson and Johnson, Merck, Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals, and Sanofi. In the letters, Trump gave the companies 60 days to extend 'Most-Favored-Nation' pricing to Medicaid and provide 'full portfolios' of drugs for Medicaid patients, guarantee Most-Favored-Nation pricing for new drugs, negotiate with 'foreign freeloading nations' and return 'increased revenues abroad' to patients in the United States, and allow Americans to directly purchase drugs at Most-Favored-Nation prices. Today, @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. If they refuse to step up, the Administration will use every tool to protect Americans from continued abusive drug pricing practices. Letter to Eli Lilly: — Rapid Response 47 (@RapidResponse47) July 31, 2025


Newsweek
19 hours ago
- Newsweek
California Removes 900,000 People From Health Care Plan
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hundreds of thousands have been removed from a health care plan in California over the course of two years, according to data from KFF, a nonprofit health policy research and news organization. About 900,000 Americans were disenrolled from Medicaid in the state as part of the unwinding process happening nationwide after Medicaid coverage was expanded following the COVID-19 pandemic. Newsweek has contacted the California Department of Public Health via email for comment. Why It Matters The unwinding process has resulted in significant drops in Medicaid enrollment across the U.S. There is now growing concern about the rising population of those without health insurance and the wider impacts this could have, such as worsening health outcomes, increasing strain on emergency services and rising medical costs. The worry has been amplified by the recent passing of President Donald Trump's One Big Beautiful Bill, in which funding cuts, a focus on "waste, fraud and abuse" and work requirements are in store for Medicaid. Many have voiced concern that the measures will result in millions losing health coverage. File photo: A doctor walks with a young boy through a hospital. File photo: A doctor walks with a young boy through a To Know In California, there were 14,285,643 covered by Medicaid in March 2023, but by March 2025, that number was 13,392,566, KFF data shows. This was because during the pandemic, some states expanded Medicaid coverage under the Affordable Care Act (ACA), causing nationwide enrollment levels to increase. Federal rules forced states to keep most Medicaid enrollees on the program, even if their eligibility status changed, until March 2023, when they were then allowed to start rolling recipients off the program. This marks a change of about 900,000, a decline that was smaller than other highly populated states like Texas, Florida and New York. In March 2025, the number of people with Medicaid coverage in California was still higher than pre-pandemic levels, by 16 percent. The reason why Medicaid coverage is unwinding at different rates in states is because "states approached the process of reviewing the eligibility of their Medicaid beneficiaries with fundamentally different strategies," Michael Sparer, professor and chair of the Department of Health Policy and Management at Columbia University, told Newsweek. He said that Florida and Texas began the review process "as fast as they could and immediately declared ineligible those beneficiaries who did not promptly respond to review notices." "There is clear evidence that many beneficiaries who were still eligible lost coverage simply because they did not timely navigate the administrative hurdles to recertification," he added. Meanwhile, he said that New York and California "were far more deliberate in how they approached the review process, thus the number who've lost their eligibility via this process is far fewer." What People Are Saying Michael Sparer, professor and chair of the Department of Health Policy and Management at Columbia University, told Newsweek: "Medicaid enrollment surged during the pandemic for several reasons, including increased unemployment combined with a requirement that in exchange for additional federal funding, states could not recertify beneficiary eligibility until the "public health emergency" was declared over. Put simply, millions signed up during the pandemic and their eligibility could only be reviewed beginning in the spring 2023. "There is reason to be quite concerned about how this has played out and also what it suggests may happen when Medicaid work requirements, which create their own set of administrative hurdles, are implemented. First, persons who are eligible for coverage should not lose coverage. Bad health outcomes will follow. Second, persons who are no longer Medicaid eligible should be guided to other options, such as subsidized ACA marketplace coverage. Finally, the variation in how states conduct Medicaid eligibility reviews leads to unfortunate inequities." What Happens Next As the unwinding continues, more reductions in enrollment are expected in California and across the country. With millions already having lost health coverage, concerns remain about access to care for low-income individuals and families.

Epoch Times
19 hours ago
- Epoch Times
What to Know About the Fight Over Planned Parenthood Funding
Funding for Planned Parenthood has been the source of legal and legislative contention in recent months since the passage of the Republican-backed One Big Beautiful Bill Act. The abortion provider has received federal funds since the early 1970s through Title X grants, as well as Medicaid reimbursements.